Clinical Trial Update: Vyndaqel Capsules Special Investigation (ATTR-CM)

View source ↗

Summary

Pfizer reports the completion of a special investigation trial evaluating Vyndaqel (tafamidis) capsules for transthyretin amyloid cardiomyopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Vyndaqel (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy | Status: COMPLETED